Review Article

Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

Table 3

Summary of discontinuation rate due to AEs and inefficacy at different time points among the included studies (12 comparative studies evidence).

RegistryStudy nameIntervention Discontinuation rate due to AEs (%)Discontinuation rate due to inefficacy (%)
6 m12 m18 m24 m36 m6 m12 m18 m24 m36 m

Biologic-naive
DREAM Flendrie et al. 2003 [1]ADA9411.011.0
ETN147.07.0
INF8324.010.0
LOHREN Marchesoni et al. 2009 [8]ADA30319.814.9
ETN24211.612.8
INF51920.420.0

Mixed (biologic pretreated and biologic-naive)
SCQM Pan et al. 2009 [13]ADA8824.77.710.712.416.2
ETN8872.87.412.515.421.1
INF5954.710.014.820.324.7
RABBIT Strangfeld et al. 2009 [14]ADA + LEF17412.021.626.027.313.123.828.031.2
ADA + MTX56612.818.823.825.012.818.522.424.632.4
ETN + LEF1448.515.719.322.19.619.922.630.6
ETN + MTX4489.913.516.318.720.610.417.120.524.530.0
INF + LEF7617.827.816.12537.443.5
INF + MTX36117.322.627.830.537.112.823.328.332.2
ADA8.3 (1622) 
13.1 (1622) 
16.9 (1622) 
18.4 (1622) 
16.2 (882) 
Pooled discontinuation rateETN5.5 (1479) 
10.1 (1479) 
14.3 (1479) 
17.1 (1479) 
20.9 (1335) 
INF10.1 (1032)
15.8 (1032) 
19.7 (956) 
24.2 (956) 
29.4 (956) 

Overall comparative evidence
ADA8.3 (1622) 
13.0 (1716) 
16.9 (1622) 
18.4 (1622) 
17.3 (1185) 
12.8 (740) 
18.7 (834) 
23.8 (740) 
26.2 (740) 
26.4 (869) 
Pooled discontinuation rateETN5.5 (1479) 
2
10.1 (1493) 
14.3 (1479) 
17.1 (1479) 
19.5 (1577) 
10.1 (592) 
17.5 (606) 
20.9 (592) 
26.0 (592) 
23.9 (690) 
INF10.1 (1032) 
16.4 (1115) 
19.7 (956) 
24.2 (956) 
26.2 (1475) 
13.3 (437) 
21.3 (520) 
29.7 (437) 
34.1 (437) 
20.0 (519) 

ADA: adalimumab; DREAM: Dutch Rheumatoid Arthritis Monitoring; ETN: etanercept; INF: infliximab; LEF: leflunomide; LOHREN: Lombardy Rheumatology Network; M: Months; MTX: methotrexate; RABBIT: rheumatoid arthritis observation of biologic therapy; SCQM: Swiss Clinical Quality Management in Rheumatic Diseases.